Skip to main content

Advertisement

Table 2 Correlation between immunological markers and clinical features of pro-B-ALL

From: Clinical-biological characteristics and treatment outcomes of pediatric pro-B ALL patients enrolled in BCH-2003 and CCLG-2008 protocol: a study of 121 Chinese children

Clinical featuresCD15CD34NG2
Neg (%)Pos (%)PNeg (%)Pos (%)PNeg (%)Pos (%)P
Gender
 Male35 (58)9 (56)0.88114 (54)55 (58)0.71227 (59)17 (57)0.861
 Female25 (42)7 (44)12 (46)40 (42)19 (41)13 (43)
Age (years)
 < 16 (10)4 (25)0.2272 (8)9 (9)0.8122 (4)8 (27)0.012
 1–1045 (75)11 (69)20 (77)67 (71)36 (78)20 (67)
 ≥ 109 (15)1 (6)4 (15)19 (20)8 (17)2 (7)
WBC
 < 50 × 109/L42 (70)12 (75)0.69518 (69)66 (69)0.98135 (76)19 (63)0.231
 ≥ 50 × 109/L18 (30)4 (25)8 (31)29 (31)11 (24)11 (37)
Prednisone response
 Good54 (90)16 (100)0.18824 (92)88 (93)0.95641 (89)29 (97)0.234
 Poor6 (10)0 (0)2 (8)7 (7)5 (11)1 (3)
MRD at day 33
 < 0.01%9 (17)3 (19)0.04211 (26)16 (21)0.0017 (18)5 (17)0.881
 0.01–1%38 (72)7 (44)10 (24)43 (57)26 (67)19 (63)
 ≥ 1%6 (11)6 (38)21 (50)16 (21)6 (15)6 (20)
MRD at day 78
 < 0.1%46 (94)10 (67)0.00518 (95)61 (84)0.21332 (89)24 (86)0.703
 ≥ 0.1%3 (6)5 (33)1 (5)12 (16)4 (11)4 (14)
  1. Italic signifies P < 0.05